ACTA ENDOCRINOLOGICA (BUC)

Introduction. It is unclear whether reversion to normoglycemia decreases overall cardiovascular events and all-cause mortality risk in the long term. We aim to investigate the magnitude of change in cardiovascular risk and mortality in patients who reverted from a prediabetes state. Methods. Three electronic databases, including PubMed, Proquest, and EBSCOHost databases, were utilized. A manual hand search of articles was also done. We selected studies that measure cardiovascular risk and all-cause mortality risk after reversion from prediabetes to normoglycemia. The following terms and its variant were used in the search strategy: ‘reversion,’ ‘prediabetes,’ ‘normoglycemia,’ cardiovascular risk,’ and ‘mortality.’ Results. Seven studies with a total of 73,845 participants were obtained. Most studies suggest that reversion of prediabetes reduced the cardiovascular and allcause mortality risk (RR: 0.50 – 0.78) compared to persistent prediabetes state or progression to diabetes with long-term follow-up ranging from 5 to 12 years, while two studies did not show significant association in CVD and all-cause morality risk. Conclusion. Although there were mixed results regarding if prediabetes poses a higher risk than normoglycemia for cardiovascular events and all-cause mortality, measures to normalize blood glucose for prediabetes should still be advocated.

Context. Obesity is a chronic disorder with excessive accumulation and hypertrophy of adipose cells. Selective sodium-glucose cotransporter-2 (SGLT2) Inhibitor has shown an effect of weight loss in several studies. However, weight loss in patients with obesity without diabetes remains unclear. Objective. This systematic review aims to address the weight loss effects of SGLT 2 inhibitors in obese subjects without diabetes. Methods. We incorporated search engines from Pubmed, EBSCO host, and Proquest. The inclusion criteria for this research were full-text, written in English, written in Bahasa Indonesia, reported the effect of SGLT 2 inhibitors for weight loss in obese patients, the design of the studies, outcomes, and the results of the study. We created a data extraction table to gather the required data for the review. The exclusion criteria for this study were incomplete outcomes, not full-text studies, case reports, literature review, and irrelevant studies. Results. A total of 451 studies were identified from research database. There are 7 studies eligible to be included in this review. Weight loss effects of SGLT2 Inhibitors were observed in all the studies included in this review. Conclusion. SGLT2 inhibitor is an effective weight loss therapy in patients with obesity without diabetes.